Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
企業コードAQST
会社名Aquestive Therapeutics Inc
上場日Jul 25, 2018
最高経営責任者「CEO」Mr. Daniel Barber
従業員数142
証券種類Ordinary Share
決算期末Jul 25
本社所在地30 Technology Dr
都市WARREN
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号07059-5166
電話番号19089411900
ウェブサイトhttps://aquestive.com/
企業コードAQST
上場日Jul 25, 2018
最高経営責任者「CEO」Mr. Daniel Barber
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし